The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Combination Antifungal Therapy for Cryptococcal Meningitis
Open accessAbstract
BACKGROUND: Combination antifungal therapy (amphotericin B deoxycholate and flucytosine) is the recommended treatment for cryptococcal meningitis but has not been shown to reduce mortality, as compared with amphotericin B alone. We performed a randomized, controlled trial to determine whether combining flucytosine or high-dose fluconazole with high-dose amphotericin B improved survival at 14 and 70 days. METHODS: We conducted a randomized, three-group, open-label trial of induction therapy for cryptococcal meningitis in patients with human immunodeficiency virus infection. All patients received amphotericin B at a dose of 1 mg per kilogram of body weight per day; patients in group 1 were treated for 4 weeks, and those in groups 2 and 3 for 2 weeks. Patients in group 2 concurrently received flucytosine at a dose of 100 mg per kilogram per day for 2 weeks, and those in group 3 concurrently received fluconazole at a dose of 400 mg twice daily for 2 weeks. RESULTS: A total of 299 patients were enrolled. Fewer deaths occurred by days 14 and 70 among patients receiving amphotericin B and flucytosine than among those receiving amphotericin B alone (15 vs. 25 deaths by day 14; hazard ratio, 0.57; 95% confidence interval [CI], 0.30 to 1.08; unadjusted P=0.08; and 30 vs. 44 deaths by day 70; hazard ratio, 0.61; 95% CI, 0.39 to 0.97; unadjusted P=0.04). Combination therapy with fluconazole had no significant effect on survival, as compared with monotherapy (hazard ratio for death by 14 days, 0.78; 95% CI, 0.44 to 1.41; P=0.42; hazard ratio for death by 70 days, 0.71; 95% CI, 0.45 to 1.11; P=0.13). Amphotericin B plus flucytosine was associated with significantly increased rates of yeast clearance from cerebrospinal fluid (-0.42 log10 colony-forming units [CFU] per milliliter per day vs. -0.31 and -0.32 log10 CFU per milliliter per day in groups 1 and 3, respectively; P<0.001 for both comparisons). Rates of adverse events were similar in all groups, although neutropenia was more frequent in patients receiving a combination therapy. CONCLUSIONS: Amphotericin B plus flucytosine, as compared with amphotericin B alone, is associated with improved survival among patients with cryptococcal meningitis. A survival benefit of amphotericin B plus fluconazole was not found. (Funded by the Wellcome Trust and the British Infection Society; Controlled-Trials.com number, ISRCTN95123928.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mice: Multivariate Imputation by Chained Equations in R
Buuren, S. V., & Groothuis-Oudshoorn, K. (2011) · Journal of Statistical Software · doi:10.18637/jss.v045.i03 · Cited by 13,870 · cited 1×
“Grades 3 and 4 11 (11) 6 (6) 14 (14) 0.”
Perfect, J. R., Dismukes, W. E., Dromer, F., Goldman, D. L., Graybill, J. R., Hamill, R. J., Harrison, T. S., Larsen, R. A., Lortholary, O., Nguyen, M.-H., et al. (2010) · Clinical Infectious Diseases · doi:10.1086/649858 · Cited by 2,660
Park, B. J., Wannemuehler, K. A., Marston, B. J., Govender, N., Pappas, P. G., & Chiller, T. M. (2009) · AIDS · doi:10.1097/qad.0b013e328322ffac · Cited by 2,014
Bretz, F., Hothorn, T., & Westfall, P. (2016) · doi:10.1201/9781420010909 · Cited by 1,233
Dexamethasone for the Treatment of Tuberculous Meningitis in Adolescents and Adults
Thwaites, G. E., Bang, N. D., Dung, N. H., Quy, H. T., Oanh, D. T. T., Thoa, N. T. C., Hien, N. Q., Thuc, N. T., Hai, N. N., Lan, N. T. N., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040573 · Cited by 1,043
Self-citationMolecular Evolution: A Phylogenetic Approach
Page, R., & Holmes, E. C. (1998) · Medical Entomology and Zoology · Cited by 979
Treatment of Cryptococcal Meningitis Associated with the Acquired Immunodeficiency Syndrome
van der Horst, C. M., Saag, M. S., Cloud, G. A., Hamill, R. J., Graybill, J. R., Sobel, J. D., Johnson, P. C., Tuazon, C. U., Kerkering, T., Moskovitz, B. L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707033370103 · Cited by 820
Infections with Cryptococcus neoformans in the Acquired Immunodeficiency Syndrome
Chuck, S. L., & Sande, M. A. (1989) · New England Journal of Medicine · doi:10.1056/nejm198909213211205 · Cited by 797
Dexamethasone for treatment of tuberculous meningitis in adolescents and adults
Tunkel, A. R. (2005) · Current Infectious Disease Reports · doi:10.1007/s11908-005-0059-0 · Cited by 671
Saag, M. S., Powderly, W. G., Cloud, G. A., Robinson, P., Grieco, M. H., Sharkey, P. K., Thompson, S. E., Sugar, A. M., Tuazon, C. U., Fisher, J. F., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201093260202 · Cited by 631
Cited by
Maziarz, E. K., & Perfect, J. R. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.006 · Cited by 698
Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches
Roemer, T., & Krysan, D. J. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019703 · Cited by 593
Cryptococcus: from environmental saprophyte to global pathogen
May, R. C., Stone, N. R. H., Wiesner, D. L., Bicanic, T., & Nielsen, K. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2015.6 · Cited by 541
Stone, N. R. H., Bicanic, T., Salim, R., & Hope, W. (2016) · Drugs · doi:10.1007/s40265-016-0538-7 · Cited by 537
Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal Meningitis
Boulware, D. R., Meya, D. B., Muzoora, C., Rolfes, M. A., Huppler Hullsiek, K., Musubire, A., Taseera, K., Nabeta, H. W., Schutz, C., Williams, D. A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312884 · Cited by 497
Limper, A. H., Adenis, A., Le, T., & Harrison, T. S. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30303-1 · Cited by 472
Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapy
Williamson, P. R., Jarvis, J. N., Panackal, A. A., Fisher, M. C., Molloy, S. F., Loyse, A., & Harrison, T. S. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.167 · Cited by 480
Hayati Rezvan, P., Lee, K. J., & Simpson, J. A. (2015) · BMC Medical Research Methodology · doi:10.1186/s12874-015-0022-1 · Cited by 459
Molecular Evolution of Antifungal Drug Resistance
Robbins, N., Caplan, T., & Cowen, L. E. (2017) · Annual Review of Microbiology · doi:10.1146/annurev-micro-030117-020345 · Cited by 441
High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
Jindani, A., Harrison, T. S., Nunn, A. J., Phillips, P. P. J., Churchyard, G. J., Charalambous, S., Hatherill, M., Geldenhuys, H., McIlleron, H. M., Zvada, S. P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314210 · Cited by 432
Antifungal Combinations for Treatment of Cryptococcal Meningitis in Africa
Molloy, S. F., Kanyama, C., Heyderman, R. S., Loyse, A., Kouanfack, C., Chanda, D., Mfinanga, S., Temfack, E., Lakhi, S., Lesikari, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1710922 · Cited by 396
Self-citationPharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients
Bellmann, R., & Smuszkiewicz, P. (2017) · Infection · doi:10.1007/s15010-017-1042-z · Cited by 389
Treatment strategies for cryptococcal infection: challenges, advances and future outlook
Iyer, K. R., Revie, N. M., Fu, C., Robbins, N., & Cowen, L. E. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00511-0 · Cited by 363
Chang, C. C., Harrison, T. S., Bicanic, T. A., Chayakulkeeree, M., Sorrell, T. C., Warris, A., Hagen, F., Spec, A., Oladele, R., Govender, N. P., et al. (2024) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00731-4 · Cited by 326
Self-citationA neglected epidemic: Fungal infections in HIV/AIDS
Armstrong-James, D., Meintjes, G., & Brown, G. D. (2014) · Trends in Microbiology · doi:10.1016/j.tim.2014.01.001 · Cited by 325
Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis
Beardsley, J., Wolbers, M., Kibengo, F. M., Ggayi, A.-B. M., Kamali, A., Cuc, N. T. K., Binh, T. Q., Chau, N. V. V., Farrar, J., Merson, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509024 · Cited by 315
Self-citationSingle-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis
Jarvis, J. N., Lawrence, D. S., Meya, D. B., Kagimu, E., Kasibante, J., Mpoza, E., Rutakingirwa, M. K., Ssebambulidde, K., Tugume, L., Rhein, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2111904 · Cited by 286
Self-citationCryptococcal meningitis: epidemiology and therapeutic options
Sloan, D., & Parris, V. (2014) · Clinical Epidemiology · doi:10.2147/clep.s38850 · Cited by 277
Antifungal Drugs: The Current Armamentarium and Development of New Agents
Robbins, N., Wright, G. D., & Cowen, L. E. (2016) · Microbiology Spectrum · doi:10.1128/microbiolspec.funk-0002-2016 · Cited by 271
Rhein, J., Morawski, B. M., Hullsiek, K. H., Nabeta, H. W., Kiggundu, R., Tugume, L., Musubire, A., Akampurira, A., Smith, K. D., Alhadab, A., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00074-8 · Cited by 183
Paradoxical Immune Responses in Non-HIV Cryptococcal Meningitis
Panackal, A. A., Wuest, S. C., Lin, Y.-C., Wu, T., Zhang, N., Kosa, P., Komori, M., Blake, A., Browne, S. K., Rosen, L. B., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004884 · Cited by 162
In Vitro and In Vivo Evaluation of APX001A/APX001 and Other Gwt1 Inhibitors against Cryptococcus
Shaw, K. J., Schell, W. A., Covel, J., Duboc, G., Giamberardino, C., Kapoor, M., Moloney, M., Soltow, Q. A., Tenor, J. L., Toffaletti, D. L., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00523-18 · Cited by 121
Denning, D. W. (2016) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2015.0468 · Cited by 117
Butts, A., Koselny, K., Chabrier-Roselló, Y., Semighini, C. P., Brown, J. C. S., Wang, X., Annadurai, S., DiDone, L., Tabroff, J., Childers, W. E., et al. (2014) · mBio · doi:10.1128/mbio.00765-13 · Cited by 102
Loyse, A., Burry, J., Cohn, J., Ford, N., Chiller, T., Ribeiro, I., Koulla-Shiro, S., Mghamba, J., Ramadhani, A., Nyirenda, R., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(18)30493-6 · Cited by 90
Self-citationKoselny, K., Green, J., DiDone, L., Halterman, J. P., Fothergill, A. W., Wiederhold, N. P., Patterson, T. F., Cushion, M. T., Rappelye, C., Wellington, M., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01061-16 · Cited by 83
Jarvis, J. N., Leeme, T. B., Molefi, M., Chofle, A. A., Bidwell, G., Tsholo, K., Tlhako, N., Mawoko, N., Patel, R. K. K., Tenforde, M. W., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciy515 · Cited by 86
Robbins, N., Spitzer, M., Yu, T., Cerone, R. P., Averette, A. K., Bahn, Y.-S., Heitman, J., Sheppard, D. C., Tyers, M., & Wright, G. D. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.018 · Cited by 78
Burden of serious fungal infections in Tanzania
Faini, D., Maokola, W., Furrer, H., Hatz, C., Battegay, M., Tanner, M., Denning, D. W., & Letang, E. (2015) · Mycoses · doi:10.1111/myc.12390 · Cited by 42
Garvey, E. P., Sharp, A. D., Warn, P. A., Yates, C. M., & Schotzinger, R. J. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky242 · Cited by 39
Fu, C., Beattie, S. R., Jezewski, A. J., Robbins, N., Whitesell, L., Krysan, D. J., & Cowen, L. E. (2022) · Genetics · doi:10.1093/genetics/iyab164 · Cited by 31
Ngan, N. T. T., Mai, N. T. H., Tung, N. L. N., Lan, N. P. H., Tai, L. T. H., Phu, N. H., Chau, N. V. V., Binh, T. Q., Hung, L. Q., Beardsley, J., et al. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15010.1 · Cited by 28
Self-citationWiederhold, N. P., Najvar, L. K., Garvey, E. P., Brand, S. R., Xu, X., Ottinger, E. A., Alimardanov, A., Cradock, J., Behnke, M., Hoekstra, W. J., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01071-18 · Cited by 27
Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs
Nielsen, K., Vedula, P., Smith, K. D., Meya, D. B., Garvey, E. P., Hoekstra, W. J., Schotzinger, R. J., & Boulware, D. R. (2016) · Medical Mycology · doi:10.1093/mmy/myw089 · Cited by 24
Hartland, K., Pu, J., Palmer, M., Dandapani, S., Moquist, P. N., Munoz, B., DiDone, L., Schreiber, S. L., & Krysan, D. J. (2016) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00111 · Cited by 24
Liu, J., Liu, J., Su, X., Yang, L., Wang, Y., Wang, A., Xu, X., Li, M., Jiang, Y., & Peng, F. (2022) · BMC Neurology · doi:10.1186/s12883-022-02803-1 · Cited by 14
Beattie, S. R., Schnicker, N. J., Murante, T., Kettimuthu, K., Williams, N. S., Gakhar, L., & Krysan, D. J. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00478 · Cited by 10
Metadata
- Authors
- Day, J. N., Chau, T. T. H., Wolbers, M., Mai, P. P., Dung, N. T., Mai, N. H., Phu, N. H., Nghia, H. D., Phong, N. D., Thai, C. Q., Thai, L. H., Chuong, L. V., Sinh, D. X., Duong, V. A., Hoang, T. N., Diep, P. T., Campbell, J. I., Sieu, T. P. M., Baker, S. G., Chau, N. V. V., Hien, T. T., Lalloo, D. G., & Farrar, J. J.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-04-04
- Volume
- 368
- Issue
- 14
- Pages
- 1291-1302
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2096006098
- Cited by
- 545
- References
- 26
- FWCI
- 39.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.